Welcome to our dedicated page for Smith & Nephew news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew stock.
Smith & Nephew plc reports news as a global medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. Coverage centers on Orthopaedics, Sports Medicine & ENT and Advanced Wound Management, including wound dressings, negative pressure wound therapy, cartilage and rotator cuff repair implants, orthopedic reconstruction, trauma and extremities products, and surgical robotics.
Recurring developments include product launches and clinical evidence for ALLEVYN COMPLETE CARE, RENASYS EDGE, CARTIHEAL AGILI-C, REGENETEN, CORI, AETOS and related platforms; conference showcases; distribution agreements; segment performance updates; share buybacks; and governance matters tied to the company’s London-listed shares and NYSE-traded ADRs.
Smith+Nephew (NYSE: SNN) announced significant findings from a randomized controlled trial for its REGENETEN Bioinductive Implant in rotator cuff repair. The interim results showed an 86% reduction in re-tear rates, with a rate of 3.5% in patients receiving the implant compared to 25% for traditional repair alone. The study was presented at the SECEC-ESSE Congress in Dublin. These results may enhance recovery for approximately 545,000 annual procedures globally, highlighting the implant's potential impact on patient outcomes and market positioning.
Smith+Nephew (NYSE: SNN) announces the OXINIUM Technology Tour of Change will be featured at the Pro Football Hall of Fame from August 4-6, 2022, to educate retired players and the community on joint replacement technology. The company partners with Hall of Fame Health to provide access to OXINIUM products. OXINIUM Technology has been recognized for its superior performance in hip and knee replacements over 20 years, showing low revision rates. Testimonials from Hall of Famers emphasize the technology's positive impact on their lives.
Smith+Nephew (LSE: SN, NYSE: SNN) is showcasing advanced joint repair solutions at the AOSSM Annual Meeting in Colorado from July 13-17, 2022. Key highlights include the REGENETEN Bioinductive Implant, aimed at treating 17 million individuals with rotator cuff diseases in the U.S., which has shown potential to expedite healing and reduce re-tears. Other innovations include the Reimagine Reconstruction portfolio for knee injuries and the CAP-FIX Suture Passer for hip repairs. The event will also feature live surgery demos and educational opportunities for surgeons.
Smith+Nephew (NYSE:SNN) has launched the WOUND COMPASS™ Clinical Support App, aimed at assisting healthcare professionals in wound assessment and decision-making. The app addresses practice variation, which negatively affects patient outcomes in chronic wound care. Validated by over 70 clinicians, it enhances nurse confidence in assessments, with 83% of non-specialists reporting it simplifies evaluations. Available on both Apple and Android, the app categorizes wounds and offers tailored treatment guidance. This innovation is part of Smith+Nephew’s commitment to improving patient care and outcomes.
Smith+Nephew (NYSE: SNN) successfully performed its first robotic-assisted surgery using the LEGION CONCELOC Cementless Total Knee System. Conducted by Dr. Cyna Khalily in Louisville, KY, this milestone enhances its portfolio of cementless knee implants and robotic technology. The procedure employs the CORI Surgical System, designed to optimize surgical efficiency by eliminating preoperative CT imaging, thus reducing costs and radiation exposure. This innovation reflects Smith+Nephew's commitment to improving surgical outcomes and employing advanced materials for knee arthroplasty.
Smith+Nephew (LSE: SN, NYSE: SNN) published a peer-reviewed article in Wounds International predicting a potential release of 3.5 billion hours of nursing time by 2030 through shared care in chronic wound management and the use of long-wear advanced foam dressings. The study highlights a global nursing shortage of 10.6 million by 2030, emphasizing the need for efficient care practices. The implementation of shared care practices could lead to an annual reallocation of over 433 million hours of clinical nursing time worldwide, enhancing patient care and optimizing resources.
Smith+Nephew (NYSE:SNN) announced the successful first total hip arthroplasty (THA) using its RI.HIP MODELER at Duke Regional Hospital. The procedure was performed by Dr. Rhett Hallows, who utilized the preoperative spinopelvic assessment tool to enhance surgical planning. In April, Dr. Thorsten Seyler executed the inaugural RI.HIP NAVIGATION procedure on the CORI Surgical System. This system aids in precise component alignment, addressing challenges in hip surgery. The innovations are expected to drive growth for the CORI Surgical System.
Healiva® announced its acquisition of two innovative cell therapy assets from Smith+Nephew (NYSE:SNN), enhancing its portfolio of chronic wound care solutions. The first asset, EpiDex®, is an autologous epidermal equivalent that facilitates surgery-free healing for chronic venous leg ulcers (VLUs), while the second, healiva®002, is an allogeneic cell therapy proven effective for hard-to-treat VLUs. This acquisition aims to expedite market launch and addresses the urgent need for effective treatments for the 36 million people suffering from chronic wounds worldwide.
Smith+Nephew (LSE: SN, NYSE: SNN) announced a peer-reviewed study published in the Advances in Wound Care Journal, demonstrating that GRAFIX Cryopreserved Placental Membrane significantly cuts diabetic foot ulcer (DFU) recurrence rates. The study analyzed over 1.3 million Medicare patients and showed a reduction of up to 58.5% in ulcer recurrence at 365 days compared to competitors. With Medicare patients spending an estimated $6-18 billion annually on DFU treatment, GRAFIX has gained coverage from Medicare and major payers, reinforcing its potential financial advantage.
Smith+Nephew (NYSE:SNN) will showcase its innovations in Orthopaedic Reconstruction and Robotics at the AAOS 2022 Annual Meeting in Chicago. The highlight is the launch of the LEGION CONCELOC Cementless Total Knee System, marking Smith+Nephew as the only U.S. company with a complete cementless knee portfolio. Their ABLE Advanced Anterior Approach for Total Hip Arthroplasty is also noteworthy for its efficiency and low complication rates. The CORI Surgical System, offering expanded indications in orthopedic procedures, will also be presented, enhancing Smith+Nephew's robotic-assisted surgery capabilities.